CL Stock Analysis: Colgate-Palmolive | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 70.953m USD | 12M Return: 3.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 492M
EPS Trend: 89.2%
Qual. Beats: -1
Rev. Trend: 89.8%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality
Colgate-Palmolive Company (NYSE: CL) is a global consumer staples manufacturer headquartered in New York, founded in 1806. It operates through two business segments: Oral, Personal and Home Care (offering products such as toothpaste, hand soaps, shampoos, deodorants, household cleaners, and fabric conditioners under brands including Colgate, Palmolive, Irish Spring, Softsoap, and Fabuloso), and Pet Nutrition (offering Hills Science Diet and Hills Prescription Diet pet foods, plus the Prime100 fresh pet food brand in Australia). Products are distributed through traditional retailers, eCommerce channels, wholesalers, distributors, dentists, veterinarians, and skin health professionals across the U.S. and international markets. As a large-cap household products company, Colgate benefits from steady demand for everyday personal care and cleaning essentials, while its Pet Nutrition segment provides exposure to the growing premium and therapeutic pet food categories, which typically command higher margins than mass-market staples.
- Pet Nutrition margin expansion on Hills Science Diet demand
- FX headwinds pressure emerging market oral care sales
- Commodity costs ease, supporting gross margin recovery
| Net Income: 2.09b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.23 > 0.02 and ΔFCF/TA 1.85 > 1.0 |
| NWC/Revenue: 0.71% < 20% (prev -5.25%; Δ 5.96% < -1%) |
| CFO/TA 0.26 > 3% & CFO 4.34b > Net Income 2.09b |
| Net Debt (7.12b) to EBITDA (3.89b): 1.83 < 3 |
| Current Ratio: 1.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (805.1m) vs 12m ago -2.12% < -2% |
| Gross Margin: 60.06% > 18% (prev 60.73%; Δ -0.67% > 0.5%) |
| Asset Turnover: 125.1% > 50% (prev 119.8%; Δ 5.24% > 0%) |
| Interest Coverage Ratio: 12.31 > 6 (EBIT TTM 3.25b / Interest Expense TTM 264.0m) |
| A: 0.01 (Total Current Assets 6.08b - Total Current Liabilities 5.93b) / Total Assets 16.6b |
| B: 1.61 (Retained Earnings 26.8b / Total Assets 16.6b) |
| C: 0.20 (EBIT TTM 3.25b / Avg Total Assets 16.6b) |
| D: 0.01 (Book Value of Equity 145.0m / Total Liabilities 16.1b) |
| Altman-Z'' = 6.64 = AAA |
| DSRI: 1.05 (Receivables 1.89b/1.73b, Revenue 20.8b/19.9b) |
| GMI: 1.01 (GM 60.73% / 60.06%) |
| AQI: 0.92 (AQ_t 0.36 / AQ_t-1 0.39) |
| SGI: 1.04 (Revenue 20.8b / 19.9b) |
| TATA: -0.14 (NI 2.09b - CFO 4.34b) / TA 16.6b) |
| Beneish M = -3.00 (Cap -4..+1) = AA |
As of June 29, 2026, the stock is trading at USD 92.07 with a total of 8,694,938 shares traded. Over the past week, the price has changed by +2.89%, over one month by +0.45%, over three months by +8.06% and over the past year by +3.85%.
Current recommended Stop Loss: 87.10 (which is 5.4% or 2.3 ATR below the current price).
Colgate-Palmolive has received a consensus analysts rating of 3.77. Therefore, it is recommended to hold CL.
- StrongBuy: 7
- Buy: 6
- Hold: 7
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 95.9 | 4.1% |
P/E Trailing = 34.3682
P/E Forward = 23.2019
P/S = 3.412
P/B = 493.7996
P/EG = 1.5987
Revenue TTM = 20.8b USD
EBIT TTM = 3.25b USD
EBITDA TTM = 3.89b USD
Long Term Debt = 7.94b USD (from longTermDebt, last quarter)
Short Term Debt = 36.0m USD (from shortTermDebt, last quarter)
Debt = 8.54b USD (from shortLongTermDebtTotal, last quarter) + Leases 566.0m
Net Debt = 7.12b USD (calculated: Debt 8.54b - CCE 1.42b)
Enterprise Value = 78.1b USD (71.0b + Debt 8.54b - CCE 1.42b)
Interest Coverage Ratio = 12.31 (Ebit TTM 3.25b / Interest Expense TTM 264.0m)
EV/FCF = 20.73x (Enterprise Value 78.1b / FCF TTM 3.77b)
FCF Yield = 4.82% (FCF TTM 3.77b / Enterprise Value 78.1b)
FCF Margin = 18.11% (FCF TTM 3.77b / Revenue TTM 20.8b)
Net Margin = 10.04% (Net Income TTM 2.09b / Revenue TTM 20.8b)
Gross Margin = 60.06% ((Revenue TTM 20.8b - Cost of Revenue TTM 8.30b) / Revenue TTM)
Gross Margin QoQ = 60.59% (prev 60.15%)
Tobins Q-Ratio = 4.70 (Enterprise Value 78.1b / Total Assets 16.6b)
Interest Expense / Debt = 3.09% (Interest Expense 264.0m / Debt 8.54b)
Taxrate = 26.12% (783.0m / 3.00b)
NOPAT = 2.40b (EBIT 3.25b * (1 - 26.12%))
Current Ratio = 1.02 (Total Current Assets 6.08b / Total Current Liabilities 5.93b)
Debt / Equity = 58.89 (Debt 8.54b / totalStockholderEquity, last quarter 145.0m)
Debt / EBITDA = 1.83 (Net Debt 7.12b / EBITDA 3.89b)
Debt / FCF = 1.89 (Net Debt 7.12b / FCF TTM 3.77b)
Total Stockholder Equity = 700.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.55% (Net Income 2.09b / Total Assets 16.6b)
RoE = 298.1% (Net Income TTM 2.09b / Total Stockholder Equity 700.0m)
RoCE = 37.63% (EBIT 3.25b / Capital Employed (Equity 700.0m + L.T.Debt 7.94b))
RoIC = 24.83% (NOPAT 2.40b / Invested Capital 9.67b)
WACC = 4.84% (E(71.0b)/V(79.5b) * Re(5.15%) + D(8.54b)/V(79.5b) * Rd(3.09%) * (1-Tc(0.26)))
Discount Rate = 5.15% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -87.41 | Cagr: -1.08%
[DCF] Terminal Value 76.51% ; FCFF base≈3.65b ; Y1≈3.92b ; Y5≈4.77b
[DCF] Fair Price = 82.59 (EV 73.2b - Net Debt 7.12b = Equity 66.1b / Shares 800.2m; r=8.35% [WACC [floored]]; 5y FCF grow 8.65% → 2.50% )
EPS Correlation: 89.22 | EPS CAGR: 6.89% | SUE: -4.0 | # QB: -1
Revenue Correlation: 89.83 | Revenue CAGR: 2.88% | SUE: 2.14 | # QB: 2
EPS current Quarter (2026-06-30): EPS=0.95 | Chg30d=-0.02% | Revisions=-68% | Analysts=17
EPS next Quarter (2026-09-30): EPS=0.92 | Chg30d=+0.10% | Revisions=-78% | Analysts=17
EPS current Year (2026-12-31): EPS=3.81 | Chg30d=+0.03% | Revisions=-56% | GrowthEPS=+3.3% | GrowthRev=+5.2%
EPS next Year (2027-12-31): EPS=4.04 | Chg30d=+0.04% | Revisions=-56% | GrowthEPS=+6.0% | GrowthRev=+3.3%
[Analyst] Revisions Ratio: -78%